PCK · ASX

PainChek Ltd (ASX:PCK)

AU$0.04

 -0.005 (-11.111%)
ASX:Live
01/07/2025 03:35:47 PM
HALO Ords GROWTH AUS Big Candle All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PCK Overview

PCK Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PCK

Website

PainChek Ltd

Telephone

61.8.9388.8290

Address

Suite 401 35 Lime Street Sydney, New South Wales (NSW) 2000

Description

PainChek Ltd. engages in the development and commercialization of mobile medical device applications. The company was founded on August 27, 2010 and is headquartered in Sydney, Australia.

PCK Price Chart

Key Stats

Market Cap

AU$71.84M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.06

Trade Value (12mth)

AU$10,994.00

1 week

32.35%

1 month

-16.67%

YTD

60.71%

1 year

63.22%

All time high

0.43

Key Fundamentals

EPS 3 yr Growth

3.70%

EBITDA Margin

-356.30%

Operating Cashflow

-$7m

Free Cash Flow Return

-727.90%

ROIC

-848.40%

Interest Coverage

N/A

Quick Ratio

1.40

Other Data

Shares on Issue (Fully Dilluted)

1649m

HALO Sector

Technology

Next Company Report Date

29-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PCK Announcements

Latest Announcements

Date Announcements

06 June 25

Application for quotation of securities - PCK

×

Application for quotation of securities - PCK

05 June 25

PainChek has productive final FDA De Novo clearance meeting

×

PainChek has productive final FDA De Novo clearance meeting

27 May 25

PainChek partners with Eldermark to expand US market reach

×

PainChek partners with Eldermark to expand US market reach

20 May 25

PainChek appoints head of Business Development for US market

×

PainChek appoints head of Business Development for US market

19 May 25

Notification of cessation of securities - PCK

×

Notification of cessation of securities - PCK

19 May 25

Notification regarding unquoted securities - PCK

×

Notification regarding unquoted securities - PCK

01 May 25

Quarterly Investor Presentation April 2025

×

Quarterly Investor Presentation April 2025

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 April 25

Quarterly update and Appendix 4C webinar

×

Quarterly update and Appendix 4C webinar

16 April 25

R&D Tax Refund, FDA Review of Adult App & Infant App Launch

×

R&D Tax Refund, FDA Review of Adult App & Infant App Launch

27 March 25

Application for quotation of securities - PCK

×

Application for quotation of securities - PCK

27 March 25

Notification regarding unquoted securities - PCK

×

Notification regarding unquoted securities - PCK

27 March 25

Notification regarding unquoted securities - PCK

×

Notification regarding unquoted securities - PCK

17 March 25

PainChek to present at NWR Virtual Healthcare Conference

×

PainChek to present at NWR Virtual Healthcare Conference

17 March 25

Update to previous announcement

×

Update to previous announcement

06 March 25

Application for quotation of securities - PCK

×

Application for quotation of securities - PCK

06 March 25

Notification regarding unquoted securities - PCK

×

Notification regarding unquoted securities - PCK

05 March 25

Notification regarding unquoted securities - PCK

×

Notification regarding unquoted securities - PCK

28 February 25

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

26 February 25

Results of Meeting

×

Results of Meeting

31 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 January 25

Quarterly update and Appendix 4C webinar

×

Quarterly update and Appendix 4C webinar

24 January 25

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

24 December 24

Notification of cessation of securities - PCK

×

Notification of cessation of securities - PCK

23 December 24

Change of Director's Interest Notice x5

×

Change of Director's Interest Notice x5

PCK Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.4 -16.0 3.4 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.01 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.9 -21.3 11.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -22.2 -19.6 -18.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.7 -87.2 53.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,146 1,310 1,481 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,146 1,310 1,481 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 1 2 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 355.6 99.2 36.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 7 9 10 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39.0 375.3 1.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -26.4 36.5 27.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 126 63 73 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -8 -9 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.0 -15.4 -8.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -774.1 -448.6 -356.3 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -8 -9 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.4 -15.5 -8.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -775.6 -449.4 -357.2 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -9 -10 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -8 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 5.7 -32.4 -9.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -584.6 -388.5 -311.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -7 -6 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 2 3 8 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -7 -6 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -67.9 9.7 -13.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -7.2 -3.3 -2.7 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 6 3 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 7 3 4 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -6 -3 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 3 Lock Lock Lock
Equity $m Lock Lock Lock Lock 5 1 1 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 5 1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.5 -86.1 93.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -86.0 -271.0 -198.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -118.6 -1,133.7 -643.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -116.2 -319.1 -972.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -87.6 -275.9 -848.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -107.1 -230.3 -727.9 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.8 0.3 0.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -127.3 -376.0 -276.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.6 1.3 1.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.6 1.3 1.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 92.7 90.6 85.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -382.6 -297.3 -246.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.6 6.1 7.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.2 3.0 2.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 28.2 25.6 31.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.7 0.6 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.7 0.6 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -696.2 -442.3 -357.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -102.4 -308.5 -227.5 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -86.0 -271.0 -198.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 4.2 3.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -118.6 -1,133.7 -643.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -118.6 -1,133.7 -643.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 140.4 59.8 49.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 140.4 59.8 49.5 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 88.6 114.2 125.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 51.8 -54.4 -76.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PCK Shortsell

Frequently Asked Questions

The current share price of PainChek Ltd (PCK:ASX) is AU$0.04.
The 52-week high share price for PainChek Ltd (PCK:ASX) is AU$0.06.
The 52-week low share price for PainChek Ltd (PCK:ASX)? is AU$0.02.
PainChek Ltd (PCK:ASX) does not pay a dividend.
PainChek Ltd (PCK:ASX) does not pay a dividend.
PainChek Ltd (PCK:ASX) does not offer franking credits.
PainChek Ltd (PCK:ASX) is classified in the Technology.
The current P/E ratio for PainChek Ltd (PCK:ASX) is .
The current share price of PainChek Ltd (PCK:ASX) is AU$0.04.
The 52-week high share price for PainChek Ltd (PCK:ASX) is AU$0.06.
The 52-week low share price for PainChek Ltd (PCK:ASX)? is AU$0.02.
PainChek Ltd (PCK:ASX) does not pay a dividend.
PainChek Ltd (PCK:ASX) does not pay a dividend.
PainChek Ltd (PCK:ASX) does not offer franking credits.
PainChek Ltd (PCK:ASX) is classified in the Technology.
The current P/E ratio for PainChek Ltd (PCK:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.